Company Overview
Snapshot
Founded in November 2009 by Aron Cohen, diagnostics.ai operates with 1–10 employees. The company has secured one funding round. In March 2020, diagnostics.ai provided labs in the UK and US with an advanced diagnostic technique leveraging artificial intelligence for faster and more accurate results, demonstrating its impact on infectious disease detection.
Business overview
diagnostics.ai specializes in developing artificial intelligence and machine learning solutions to enhance diagnostic accuracy and reduce costs within the healthcare sector. The company's core technology, pcr.ai, automates the analysis of complex data generated during the qPCR process, streamlining the detection, diagnosis, and tracking of infectious diseases. This innovation accelerates analysis, minimizes the need for specialized technicians, and eliminates interpretation errors, serving laboratories, hospitals, healthcare centers, and providers in markets including the UK, US, and Israel.
Strategic signal
In March 2020, diagnostics.ai gained significant traction by providing its AI-powered diagnostic technology to labs in the UK and US for rapid and accurate coronavirus testing. This development highlights the company's capability to deliver critical, scalable solutions during public health crises, validating its technology's versatility and immediate market relevance for infectious disease diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What is diagnostics.ai's core technology?
- diagnostics.ai's core technology, pcr.ai, uses artificial intelligence and machine learning to automate the analysis of complex data from the qPCR process. This streamlines the detection, diagnosis, and tracking of infectious diseases by providing reliable, standardized results for positive, negative, quantitation, and CT/Cq in seconds.
- How has diagnostics.ai contributed to infectious disease diagnostics?
- In March 2020, diagnostics.ai provided labs in the UK and US with an advanced diagnostic technique that uses artificial intelligence for faster and more accurate results, particularly for coronavirus testing. This technology is generic and can analyze any virus or bacteria, significantly accelerating the diagnostic process.
- What significant partnership did diagnostics.ai establish in 2018?
- In January 2018, Viapath, one of the largest pathology service providers in the UK, agreed to implement diagnostics.ai's artificial intelligence technology. The implementation began in February 2018 at Viapath's South London Specialist Virology Centre to automate the analysis and reporting of molecular diagnostics results, improving accuracy and standardization.
- Has diagnostics.ai received any industry recognition?
- In August 2017, diagnostics.ai, then known as Azure PCR Ltd, won the Digital Health 2017 award for 'Best Data-Driven Innovation'. This award recognized the company's machine learning technology for automating precision molecular diagnostics, which reduces testing time and cost while increasing accuracy.
- What was an early application of diagnostics.ai's technology?
- In March 2014, Azure PCR, a Jerusalem-based subsidiary of diagnostics.ai, developed automatic DNA analysis technology for detecting, diagnosing, and tracking infectious diseases. This technology was utilized in global collaborations, including the Johns Hopkins-based PERCH study, to help curb the spread of viruses in real time.